The EHA Research Roadmap: Malignant Lymphoid Diseases

Abstract

In 2016, the European Hematology Association (EHA) published the EHA Roadmap for European Hematology Research 1 aiming to highlight achievements in the diagnostics and treatment of blood disorders and to better inform European policy makers and other stakeholders about the urgent clinical and scientific needs and priorities in the field of hematology. Each section was coordinated by 1 to 2 section editors who were leading international experts in the field. In the 5 years that have followed, advances in the field of hematology have been plentiful. As such, EHA is pleased to present an updated Research Roadmap, now including 11 sections, each of which will be published separately. The updated EHA Research Roadmap identifies the most urgent priorities in hematology research and clinical science, therefore supporting a more informed, focused, and ideally a more funded future for

The Updated European Hematology Association Research Roadmap

“…These updates and new developments have now been taken into account in the new EHA Research Roadmap articles. In 2019, there was already an update on the EHA Research Roadmap on Hemoglobinopathies and Thalassemia, 2 and since June 2021, we have published the new chapters on each of the EHA Research Roadmap topics: Hematopoietic Stem Cell Gene Therapy, Hematopoietic Stem Cells and Allotransplantation, Transfusion Medicine, Infections in Hematology, Normal Hematopoiesis, Anemias, Blood Coagulation and Hemostatic Disorders, Malignant Lymphoid Diseases, Malignant Myeloid Diseases, Platelet Disorders, and Immune‐based Therapies for Hematological Malignancies 3–13 …”

“…In 2019, there was already an update on the EHA Research Roadmap on Hemoglobinopathies and Thalassemia, 2 and since June 2021, we have published the new chapters on each of the EHA Research Roadmap topics: Hematopoietic Stem Cell Gene Therapy, Hematopoietic Stem Cells and Allotransplantation, Transfusion Medicine, Infections in Hematology, Normal Hematopoiesis, Anemias, Blood Coagulation and Hemostatic Disorders, Malignant Lymphoid Diseases, Malignant Myeloid Diseases, Platelet Disorders, and Immune-based Therapies for Hematological Malignancies. [3][4][5][6][7][8][9][10][11][12][13] We hope you find this series of updated EHA Research Roadmap articles of interest and of value when you write manuscripts or project applications and when you interact with policy makers or the general public.…”